GDF-8, also known as myostatin (MSTN), belongs to the TGF-β superfamily and is a key negative regulator of skeletal muscle proliferation, differentiation, and lipid/glucose metabolism. It participates in physiological processes such as muscle development, adipocyte differentiation, and tissue fibrosis through the ActRIIA/B-Smad2/3 pathway, making it a hot research target for muscle atrophy and metabolic disorders.

https://doi.org/10.3389/fendo.2022.878069

Receptor Binding and Membrane Receptor Activation

Mature GDF-8 homodimers specifically recognize and bind to type II receptors ActRIIA and ActRIIB on the cell membrane, inducing conformational changes that recruit and phosphorylate type I receptors ALK4/ALK5, initiating membrane surface signaling.

Intracellular Smad Signal Transduction

Activated type I receptors catalyze the phosphorylation of intracellular Smad2 and Smad3. Phosphorylated Smad2/3 forms heteromeric complexes with the common mediator Smad4, which translocate into the nucleus.

Nuclear Transcriptional Regulation

The complexes bind to promoter regions of target genes in the nucleus, regulating downstream gene transcription and participating in various physiological processes such as cell proliferation, differentiation, lipid/glucose metabolism, and tissue fibrosis.

UloveBio's high-activity GDF-8 protein supports cutting-edge research on muscle and metabolic targets!

Universal GDF-8 Recombinant Protein: Human/Mouse/Rat GDF-8 Protein (UA040576)

Activity: Determined by its ability to inhibit the proliferation of MPC-11 cells. The expected IC50 for this effect is 40-53 ng/ml.

Purity: >95% as determined by RP-HPLC.

1. Drug Development: Screening GDF-8 neutralizing antibodies, ActR receptor inhibitors, and peptide-based candidate molecules.

2. Biomarkers: Cell/animal model construction for evaluating the efficacy of myostatin pathway interventions.

3. Signaling Mechanisms: Investigating Smad pathway regulation, muscle satellite cell differentiation, and lipid metabolic reprogramming.

4. Model Construction: In vitro cell induction, mouse muscle atrophy/obesity modeling, and functional phenotype validation.

Summary

GDF-8, as a core negative regulator of skeletal muscle growth in the TGF-β superfamily, involves multi-level fine-tuning of its signaling pathway, including ligand activation, receptor complex formation, and Smad-dependent/independent signal transduction. It is a critical target in muscle development, metabolic regulation, and tissue fibrosis research. UloveBio's universal GDF-8 recombinant protein (UA040576), covering human, mouse, and rat species, has been validated for bioactivity in MPC-11 cell proliferation inhibition assays with >95% purity. It effectively supports ligand-receptor binding analysis, neutralizing antibody screening, and cellular functional validation across species. Complementary pathway proteins (ActRIIA/IIB, ALK4/ALK5) and activity detection kits provide a comprehensive toolkit for studying GDF-8-mediated signal transduction mechanisms, from target binding to phenotypic evaluation.